Targeting FLT3 Mutations in Acute Myeloid Leukemia
AbstractThe FMS-like tyrosine kinase 3 (FLT3) pathway has an important role in cellular proliferation, survival, and differentiation. Acute myeloid leukemia (AML) patients with mutated FLT3 have a large disease burden at presentation and a dismal prognosis. A number of FLT3 inhibitors have been developed over the years. The first-generation inhibitors are largely non-specific, while the second-generation inhibitors are more specific and more potent. These inhibitors are used to treat patients with FLT3-mutated AML in virtually all disease settings including induction, consolidation, maintenance, relapse, and after hematopoietic cell transplantation (HCT). In this article, we will review the use of FLT3 inhibitors in AML. View Full-Text
Share & Cite This Article
El Fakih, R.; Rasheed, W.; Hawsawi, Y.; Alsermani, M.; Hassanein, M. Targeting FLT3 Mutations in Acute Myeloid Leukemia. Cells 2018, 7, 4.
El Fakih R, Rasheed W, Hawsawi Y, Alsermani M, Hassanein M. Targeting FLT3 Mutations in Acute Myeloid Leukemia. Cells. 2018; 7(1):4.Chicago/Turabian Style
El Fakih, Riad; Rasheed, Walid; Hawsawi, Yousef; Alsermani, Maamoun; Hassanein, Mona. 2018. "Targeting FLT3 Mutations in Acute Myeloid Leukemia." Cells 7, no. 1: 4.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.